Treatment with atorvastatin decreased IL-6, MCP-1, and TNF-α mRNA levels by 39% (P < 0.05), 39% (P < 0.05), and 30% (P < 0.01), respectively, compared with the CI-AKI group. The gene discussed is CCL2; the disease is acute kidney injury.